kenalog 40 mg/ml injektionsvæske, suspension
bristol-myers squibb ab - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
ibuprofen "bril" 200 mg filmovertrukne tabletter
bristol laboratories ltd. - ibuprofen - filmovertrukne tabletter - 200 mg
ibuprofen "bril" 400 mg filmovertrukne tabletter
bristol laboratories ltd. - ibuprofen - filmovertrukne tabletter - 400 mg
ibuprofen "bril" 600 mg filmovertrukne tabletter
bristol laboratories ltd. - ibuprofen - filmovertrukne tabletter - 600 mg
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - andre hjertepræparater - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
diclocil 1 g pulver til injektions-/infusionsvæske, opløsning
bristol-myers squibb ab - dicloxacillinnatrium (vandfrit) - pulver til injektions-/infusionsvæske, opløsning - 1 g
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
empliciti
bristol-myers squibb pharma eeig - elotuzumab - multipelt myelom - antineoplastiske midler - empliciti er indiceret i kombination med lenalidomid og dexamethason til behandling af myelomatose hos voksne patienter, der har modtaget mindst én tidligere behandling (se afsnit 4. 2 og 5.
evotaz
bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infektioner - antivirale midler til systemisk anvendelse - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.